TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02859103
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
Study: NCT00935311
Drug: ABT-712 Extended-release
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-712 extended-release tablet
Study: NCT00935311
Drug: Hydrocodone/Acetaminophen Immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen immediate-release tablet
Study: NCT00935311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00870012
Drug: Lepicol probiotic & prebiotic formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
Study: NCT03539718
Drug: Taurolidine heparin
Normalized name: heparin / taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolock-hep 500 at end of session
Study: NCT03539718
Drug: Heparin Sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium 5000 at end of session
Study: NCT02959697
Drug: Subcut. + Subconj. Xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
Study: NCT01006694
Drug: Guideline Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline Antidepressant Medication, following the VN National Mental Health plan.
Study: NCT04094857
Drug: HBN-1
Normalized name: Hydroxybutyrate-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02259946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01160263
Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.
Study: NCT03920254
Drug: TD-1473 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT03920254
Drug: TD-1473 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description
Study: NCT02045095
Drug: MLN7243
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).
Study: NCT04031859
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
Study: NCT02473900
Drug: HIP1403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75mg
Study: NCT02473900
Drug: HGP0919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir phosphate 75mg
Study: NCT02058251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will self-administer a 40 IU dose of intranasal saline.
Study: NCT00616772
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT00616772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT01680939
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/kg PO q6hrs
Study: NCT00074867
Drug: CP-547,632
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02380742
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
Study: NCT01809808
Drug: Medications for acromegaly
Approvals — FDA: no, EMA: no, PMDA: no
Description: (non-experimental) standard procedure
Study: NCT06081803
Drug: Repatha®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repatha® 140mg x 3 pens subcutaneous injection
Study: NCT00580073
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
Study: NCT02223338
Drug: Standard Aseptic Technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
Study: NCT03518112
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03518112
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03518112
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03518112
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT02121314
Drug: intravenous administration of 1st line TB drugs, day 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
Study: NCT00570310
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
Study: NCT02481791
Drug: Remifentanil and/or propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
Study: NCT02481791
Drug: Remifentanil and/or propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
Study: NCT00909506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day).
Study: NCT00988988
Drug: 1% Steroid Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
Study: NCT01105936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo caplets
Study: NCT04921657
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01841489
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg GS-9973 (Formulation 1)
Study: NCT01841489
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
Study: NCT01841489
Drug: Treatment G
Normalized name: VanaLice Lice Killing Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg GS-9973 (Reference formulation)
Study: NCT01841489
Drug: Treatment H
Normalized name: Walgreens Lice Treatment Homeopathic Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
Study: NCT01841489
Drug: Treatment I
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
Study: NCT00988988
Drug: topical placebo cream with no active ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream to be applied immediately after injection and repeated as needed.
Study: NCT03329846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified day
Study: NCT01144091
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study: NCT00446641
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 tablet twice a day matching for cilostazol
Study: NCT01243723
Drug: Eductyl suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: One suppository every morning during 21 days
Study: NCT01243723
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: One suppository every morning during 21 days
Study: NCT03066193
Drug: Dronabinol and Palmitoylethanolamide
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
Study: NCT04112303
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT00080301
Drug: Ixabepilone + Capecitabine
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Study: NCT00080301
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
Study: NCT00496379
Drug: ZK219477
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously over approximately 30 minutes once every 3 weeks
Study: NCT03787550
Drug: The Sedatives, analgesics and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
Study: NCT01934868
Drug: prolotherapy solution of 20% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
Study: NCT02414919
Drug: ParaGard
Normalized name: ParaGard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper T380A
Study: NCT02278861
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin - 10mg/day (one pill) after lunch for six months
Study: NCT02278861
Drug: Tretinoin 0,05% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
Study: NCT02598440
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants wil receive once-monthly oral ibandronate (150 mg tablet)
Study: NCT01729819
Drug: Placebo orally disintegrating tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04096144
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
Study: NCT03018041
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in Arms.
Study: NCT02393937
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Study: NCT01818596
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Study: NCT01801774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01784250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic a drug
Study: NCT00744731
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 1 week
Study: NCT00488059
Drug: Optimized background ARV
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00061893
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. \[Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.\] .
Study: NCT00061893
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Study: NCT00061893
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
Study: NCT00666939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo 30 minutes prior to bedtime
Study: NCT03967847
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Ketorolac
Study: NCT03669562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion liposome control
Study: NCT00135525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01047436
Drug: Artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
Study: NCT04539262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an aerosolized solution
Study: NCT00377455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
Study: NCT00309452
Drug: Medications
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
Study: NCT01678313
Drug: Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)
Normalized name: doxazosin 4 MG
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study group
Study: NCT02640755
Drug: Multiple dose AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual TORC1/TORC2 inhibitor
Study: NCT04159701
Drug: LY3454738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04159701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00765804
Drug: EGP-437 with EyeGate® II System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
Study: NCT03731091
Drug: Enstilar® foam (LEO Pharma Inc.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 4 weeks (28 days)
Study: NCT03738137
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil is applied.
Study: NCT03301350
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
Study: NCT03301350
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
Study: NCT03465007
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
Study: NCT03465007
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
Study: NCT00771667
Drug: Placebo (IP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction phase (Week 0-8) (IP) - Placebo IV group
Study: NCT00771667
Drug: Placebo IV - Responder - Placebo SC (MP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
Study: NCT00664846
Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
Study: NCT01024920
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF inhibitor
Study: NCT00664846
Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
Study: NCT02090309
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
Study: NCT02090309
Drug: normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of 5 ml normal saline 0.9% as a single bolus.
Study: NCT04097080
Drug: NBTX-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug group will receive 6 doses of NBTX-001 given three times a week.
Study: NCT04097080
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will receive reconstituted air given three times a week.
Study: NCT01554189
Drug: MK-8325
Normalized name: vitamin MK 7
DrugBank: MK-8245 (DB13024)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)